Applications of (2S)-N-(2,6-Dimethylphenyl)-2-Piperidinecarboxamide in Industrial Manufacturing

As the original manufacturer of (2S)-N-(2,6-Dimethylphenyl)-2-Piperidinecarboxamide, we supply this advanced chemical intermediate for downstream sectors that demand strict process control, high purity, and traceability. Below are verified industrial applications that utilize this compound, each structured with compliance, dosage, process, and final product specifics.

1. Local Anesthetic API Synthesis

This compound serves as a key amide intermediate in the synthesis of certain local anesthetics for pharmaceutical use. Manufacturing routes leverage its distinct stereochemistry to produce active pharmaceutical ingredients with high enantiomeric purity, necessary for injectable and topical formulations. Full traceability from raw material procurement through multi-step synthesis supports quality assurance and global batch registration.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• US Pharmacopoeia (USP) Monographs for related anesthetic APIs
• European Pharmacopoeia (Ph. Eur.) Standards
• FDA 21 CFR Part 210/211 cGMP

Typical usage ratio

• Employed as a core intermediate at a 1:1 molar ratio relative to subsequent coupling agents. Final dosage adjusted according to process yield and required enantiomer content. Typical for batch reactor runs scaling from 50–500 kg.

Downstream process integration

• Introduced in the amide bond formation step, following initial aromatic amination and prior to chiral resolution or further modification (e.g., N-alkylation). Utilized under temperature-controlled, inert atmosphere conditions to maintain product fidelity.

Final product types

• Injectable local anesthetic API (e.g., ropivacaine derivatives)
• Topical anesthetic gels and creams
• Hospital-grade anesthetic cartridges
• Bulk intermediates for further API synthesis

2. Chiral Building Block for Specialty Chemical Synthesis

The compound is widely used by manufacturers of specialty chiral chemicals as a building block for advanced intermediates. Owing to its well-defined (2S) stereochemistry and aromatic substitution, it facilitates synthesis of molecules required in fine chemical production and catalyst design, where chiral purity and lot reproducibility are critical to final material performance.

Industry compliance standards

• ISO 9001:2015 Quality Management System
• REACH Registration (EC No 1907/2006) for European market entry
• GMP guidelines where applicable to chiral intermediate supply
• Lot release via NMR and HPLC enantiopurity analysis (≥99% ee)

Typical usage ratio

• Integrated at 5–25% weight basis in stepwise, multi-component chiral molecule assembly. Precise loading determined by downstream reaction stoichiometry and catalyst compatibility in organometallic or enzymatic conversions.

Downstream process integration

• Employed at the compound assembly or coupling stage, proceeding after protecting group introduction and preceding oxidative or reductive transformations. In-process controls verify enantiopurity and manage carryover of starting material.

Final product types

• Chiral ligands for metal catalysis
• Asymmetric synthesis intermediates
• Optical resolution reagents
• Custom specialty fine chemicals for R&D scale and pilot scale supply

3. Intermediate for Veterinary Drug Formulation

This material is incorporated in the upstream synthesis of veterinary anesthetic compounds, particularly those administered for large animal surgical procedures. Its chemical structure allows for targeted modification and purity critical for regulatory submission and subsequent formulation into sterile veterinary products distributed to agricultural and clinical end users.

Industry compliance standards

• Veterinary cGMP (VICH GL43, GL9)
• US FDA Guidance for Industry #205 for Veterinary APIs
• European Directorate for the Quality of Medicines (EDQM) Certificates of Suitability
• ISO 17025 Analytical Testing Certificate

Typical usage ratio

• Dosed as a primary synthetic intermediate at a 0.8–1.1 molar equivalence, optimized in multi-kilogram reactor loads per finished active batch requirement for veterinary injectable solutions or tablets.

Downstream process integration

• Introduced after aromatic precursor preparation, prior to esterification or salt formation unique to veterinary drug requirements. Controlled atmosphere and monitored temperature during amide coupling to prevent degradation.

Final product types

• Sterile injectable veterinary anesthetics
• Preformulated large animal anesthesia drugs
• Active intermediates for combination therapy preparations
• Batched bulk for contract sterile fill-finish

4. Research Reagents in Analytical Chemistry

R&D and analytical labs use the compound as a reference standard and derivatization reagent in stereochemical analysis workflows. Its defined structure enables laboratories to calibrate chiral column separations, validate synthetic routes, and provide traceable support for QC departments engaged in pharmaceutical and chemical method development.

Industry compliance standards

• ISO/IEC 17025 Laboratory Accreditation
• GLP (Good Laboratory Practice) for analytical reagent qualification
• USP Reference Standards and EP Reference Substances Guidance
• OECD Principles of Good Laboratory Practice

Typical usage ratio

• Applied at 1–10 mg/mL in calibration samples for HPLC or SFC method development, or at defined parts-per-million levels in QC traceability programs. Each batch tailored to instrument sensitivity and sample throughput.

Downstream process integration

• Weighing and dissolution of the material in analytical grade solvents, followed by spiking into standard and unknown samples. Used as primary calibration control or in verification of process intermediates during method validation campaigns.

Final product types

• Analytical standards for QC and laboratory proficiency testing
• Reference substances for chiral method validation
• Internal standards for pharmaceutical analysis
• Chiral resolution benchmarks for process QC labs